Literature DB >> 11000002

BCX-1812 (RWJ-270201): discovery of a novel, highly potent, orally active, and selective influenza neuraminidase inhibitor through structure-based drug design.

Y S Babu1, P Chand, S Bantia, P Kotian, A Dehghani, Y El-Kattan, T H Lin, T L Hutchison, A J Elliott, C D Parker, S L Ananth, L L Horn, G W Laver, J A Montgomery.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2000        PMID： 11000002     DOI： 10.1021/jm0002679

Source DB:  PubMed          Journal:  J Med Chem        ISSN： 0022-2623            Impact factor:   7.446


× No keyword cloud information.
  106 in total

1.  A validation study on the practical use of automated de novo design.

Authors:  Martin Stahl; Nikolay P Todorov; Tim James; Harald Mauser; Hans-Joachim Boehm; Philip M Dean
Journal:  J Comput Aided Mol Des       Date:  2002-07       Impact factor: 3.686

2.  Assembly of endocytic machinery around individual influenza viruses during viral entry.

Authors:  Michael J Rust; Melike Lakadamyali; Feng Zhang; Xiaowei Zhuang
Journal:  Nat Struct Mol Biol       Date:  2004-05-02       Impact factor: 15.369

3.  Therapeutic activity of intramuscular peramivir in mice infected with a recombinant influenza A/WSN/33 (H1N1) virus containing the H275Y neuraminidase mutation.

Authors:  Yacine Abed; Andrés Pizzorno; Guy Boivin
Journal:  Antimicrob Agents Chemother       Date:  2012-06-04       Impact factor: 5.191

Review 4.  Neuraminidase inhibitors for influenza B virus infection: efficacy and resistance.

Authors:  Andrew J Burnham; Tatiana Baranovich; Elena A Govorkova
Journal:  Antiviral Res       Date:  2013-09-04       Impact factor: 5.970

5.  Implications of protein conformations to modifying novel inhibitor Oseltamivir for 2009 H1N1 influenza A virus by simulation and docking studies.

Authors:  Sudha Singh; Anvita Gupta Malhotra; Mohit Jha; Khushhali Menaria Pandey
Journal:  Virusdisease       Date:  2018-09-01

6.  Phase III randomized, double-blind study comparing single-dose intravenous peramivir with oral oseltamivir in patients with seasonal influenza virus infection.

Authors:  Shigeru Kohno; Muh-Yong Yen; Hee-Jin Cheong; Nobuo Hirotsu; Tadashi Ishida; Jun-ichi Kadota; Masashi Mizuguchi; Hiroshi Kida; Jingoro Shimada
Journal:  Antimicrob Agents Chemother       Date:  2011-08-08       Impact factor: 5.191

7.  Efficacy of single intravenous injection of peramivir against influenza B virus infection in ferrets and cynomolgus macaques.

Authors:  Mitsutaka Kitano; Yasushi Itoh; Makoto Kodama; Hirohito Ishigaki; Misako Nakayama; Hideaki Ishida; Kaoru Baba; Takahiro Noda; Kenji Sato; Yoichiro Nihashi; Takushi Kanazu; Ryu Yoshida; Ryuzo Torii; Akihiko Sato; Kazumasa Ogasawara
Journal:  Antimicrob Agents Chemother       Date:  2011-08-15       Impact factor: 5.191

8.  Analysis of oseltamivir resistance substitutions in influenza virus glycoprotein neuraminidase using a lentivirus-based surrogate assay system.

Authors:  Jennifer Tisoncik-Go; Katie S Cordero; Lijun Rong
Journal:  Virol Sin       Date:  2013-02-06       Impact factor: 4.327

9.  Evaluation of neuraminidase enzyme assays using different substrates to measure susceptibility of influenza virus clinical isolates to neuraminidase inhibitors: report of the neuraminidase inhibitor susceptibility network.

Authors:  N T Wetherall; T Trivedi; J Zeller; C Hodges-Savola; J L McKimm-Breschkin; M Zambon; F G Hayden
Journal:  J Clin Microbiol       Date:  2003-02       Impact factor: 5.948

Review 10.  The role of medical structural genomics in discovering new drugs for infectious diseases.

Authors:  Wesley C Van Voorhis; Wim G J Hol; Peter J Myler; Lance J Stewart
Journal:  PLoS Comput Biol       Date:  2009-10-26       Impact factor: 4.475
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.